Article

First-line hepatic arterial infusion chemotherapy plus lenvatinib and PD-(L)1 inhibitors versus systemic chemotherapy alone or with PD-(L)1 inhibitors in unresectable intrahepatic cholangiocarcinoma: a real-world study

2024-04-12

Abstract excerpt

<h4>Purpose: </h4> Limited treatment options exist for unresectable intrahepatic cholangiocarcinoma (ICC), with systemic chemotherapy (SC) serving as the primary approach. This study aimed to assess the effectiveness of first-line hepatic arterial infusion chemotherapy (HAIC) in combination with lenvatinib and PD-(L)1 inhibitors (HLP) compared to SC combined with PD-(L)1 inhibitors (SCP) or SC alone in treating un...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0d07aff9-ce2c-5962-9a36-db08a72b8aba
DOI: 10.21203/rs.3.rs-4230875/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

First-line hepatic arterial infusion chemotherapy plus lenvatinib and PD-(L)1 inhibitors versus systemic chemotherapy alone or with PD-(L)1 inhibitors in unresectable intrahepatic cholangiocarcinoma: a real-world studyDOI 10.21203/rs.3.rs-4230875/v1Read

Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy (HAIC) Versus Systemic Therapy in Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-AnalysisSemantic proximity Read

Chemotherapy and targeted therapy for advanced biliary tract cancers：An umbrella reviewSemantic proximity Read

Ivosidenib for IDH1-Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real-World Study.Semantic proximity Read

Patient Outcomes in Resected Combined Hepatocellular Cholangiocarcinoma (cHCC-ICC) and Intrahepatic Cholangiocarcinoma: A Single Center StudySemantic proximity Read

Intrahepatic cholangiocarcinoma: current management and emerging therapies.Semantic proximity Read

Notable-HCC: A phase Ib trial of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with early stage resectable hepatocellular carcinomaSemantic proximity Read

FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation.Semantic proximity Read

Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes.Semantic proximity Read

Therapy for advanced cholangiocarcinoma: Current knowledge and future potential.Semantic proximity Read

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.Semantic proximity Read

Systemic treatment of advanced or recurrent biliary tract cancer.Semantic proximity Read

Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis.Semantic proximity Read